<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124512</url>
  </required_header>
  <id_info>
    <org_study_id>14-0136-F1V</org_study_id>
    <secondary_id>UL1TR000117</secondary_id>
    <secondary_id>1R21DK100258-01A1</secondary_id>
    <nct_id>NCT02124512</nct_id>
  </id_info>
  <brief_title>Blood Lipopolysaccharide (LPS) Rifaximin Study</brief_title>
  <official_title>Dietary Fat, Lipoprotein and Lipopolysaccharide: Role in Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Kern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic syndrome is a condition involving elevated levels of fat in the blood, a tendency
      towards diabetes, hypertension, and too much fat around the abdomen (an increased waistline).
      Individuals with metabolic syndrome often have impaired glucose tolerance, which is a
      condition where blood sugar is normal when fasting (before eating), but is too high after
      drinking a sugary drink. This is due to an abnormality in the body's sensitivity to insulin
      (insulin resistance), which is due in part to an inability of the muscle to take up glucose.

      People with metabolic syndrome have inflammation in their fat tissue and in their blood
      stream, and the changes in the level of inflammatory chemicals produced by cells in your fat
      tissues will be studied. One possible source of the inflammation may be the bacteria in the
      intestine. When individuals eat fatty foods, some of the bacterial products become attached
      to the fat in their blood and then get directed to fat tissue. The investigators wish to
      determine whether individuals have an excessive amount of inflammation in their fat tissues,
      and whether this inflammation comes from the bacteria in their intestines. To determine this,
      the investigators wish to treat individuals with an antibiotic that reduces the bacteria in
      their intestines and in their blood, and determine whether this reduces their overall level
      of inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled proof of concept study that will examine the
      investigational drug Rifaximin Soluble Solid Dispersion (SSD) ability to reduce gut
      microbiota and thereby reduce adipose inflammation and improve insulin resistance.

      Each subject enrolled will undergo a fat tolerance test with a high-fat meal, an oral glucose
      tolerance test, a fat biopsy, and a euglycemic clamp. Following their successful completion
      of those procedures subjects will be randomized to study treatment. That treatment will
      involve receiving the investigational drug,80 mg per day of rifaximin-soluble solid
      dispersion (SDD), or placebo for 12 weeks. All procedures will be performed on the Clinical
      Services Core of the CCTS. The initial visit will involve informed consent, and routine labs
      (comprehensive metabolic panel, lipid panel, TSH, CBC with platelets). These routine labs are
      for safety purposes and to rule out exclusionary disorders. A stool sample will also be
      collected and frozen for possible future analysis of bacterial microflora.

      Subjects will be asked to allow the principal investigator to bank blood and tissue samples
      collected during this study that are not used for other study-related tests. No additional
      blood or tissue samples will be collected. If the subject agrees to the banking of their
      blood and tissue samples they will be stored in the Principal Investigator's laboratory at
      the University of Kentucky for an indefinite period of time or until they are used up. Stored
      samples will be used for future research testing to learn about how to prevent, detect, or
      treat insulin resistance, metabolic syndrome, diabetes or other health problems.

      Each subject will undergo total body composition testing using a total body dual-energy x-ray
      absorptiometry (DXA) scan. The DXA scan measures the subject's bond density and body fat.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating LPS</measure>
    <time_frame>0, 4 and 8 hours at Baseline, and 0, 4 and 8 hours after 12 weeks of treatment</time_frame>
    <description>Plasma lipopolysaccharide (LPS) will be measured both in the fasting state and after a lipid-rich meal in obese subjects (Pre-Treatment: 0, 4 and 8 hr timepoints). The subjects will then be treated with the antibiotic rifaximin for 12 weeks to substantially reduce gut bacteria. LPS measurements at fasting and after a lipid-rich meal will be repeated (Post-Treatment: 0, 4 and 8 hr timepoints). The lipid tolerance tests before and after treatment with rifaximin will be assessed to determine whether there is a reduction in post-prandial LPS. LPS measurements were obtained using a modified LAL Assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tissue Inflammation</measure>
    <time_frame>Pre-Treatment (baseline) and Post-Treatment (12 weeks after baseline).</time_frame>
    <description>Subjects will undergo a baseline fat biopsy (pre-treatment). They will then be treated with rifaximin for 12 weeks and biopsies will be repeated to determine if disruption of the microbiota reduces tissue inflammation. Data are reported as normalized mRNA expression levels (arbitrary units) of TNFalpha.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Improved Insulin Sensitivity</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>We hypothesize that a change in the microbial flora with rifaximin will alter plasma LPS, adipose tissue inflammation, and insulin sensitivity. Therefore, we will examine, before and after rifaximin/placebo treatment: 1. LPS associated with lipoproteins, 2. insulin sensitivity and hepatic glucose production, 3. plasma inflammatory markers (TNFα, IL-6, MCP-1, adiponectin), 4. adipose inflammatory markers (CD68, MCP1, TNFα, PAI1, IL12, IL10, TLR4 and others).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Obese</condition>
  <condition>Insulin Resistance</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Arm 1 Rifaximin SSD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin SSD</intervention_name>
    <description>Study Drug dosing will be 80 mg SSD once daily</description>
    <arm_group_label>Arm 1 Rifaximin SSD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>80 mg placebo once daily</description>
    <arm_group_label>Arm 2 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese

          -  Insulin resistance or metabolic syndrome

          -  Body Mass Index between 27 and 45

          -  Waist circumference &gt;40&quot; (M) or &gt;35&quot; (F)

          -  Impaired glucose tolerance (IGT)

          -  Normal glucose tolerance (NGT) with at least three features of MetS

          -  A1C &lt;6.5

          -  Blood pressure 130/85

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Recent or unstable cardiovascular disease

          -  cancer,

          -  Renal insufficiency (GFR&lt;30)

          -  Steroid use

          -  chronic inflammatory conditions

          -  Anticoagulant use

          -  Lipodystrophy

          -  Irritable Bowel Syndrome

          -  Allergy to local anesthetic

          -  Lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phililp Kern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky Center for Clinical and Translational Science</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 23, 2014</study_first_submitted>
  <study_first_submitted_qc>April 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <results_first_submitted>July 16, 2019</results_first_submitted>
  <results_first_submitted_qc>August 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2019</results_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Philip Kern</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>obese</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02124512/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02124512/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1 Rifaximin SSD</title>
          <description>Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
Rifaximin SSD: Study Drug dosing will be 80 mg SSD once daily</description>
        </group>
        <group group_id="P2">
          <title>Arm 2 Placebo</title>
          <description>Placebo
Placebo: 80 mg placebo once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1 Rifaximin SSD</title>
          <description>Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
Rifaximin SSD: Study Drug dosing will be 80 mg SSD once daily</description>
        </group>
        <group group_id="B2">
          <title>Arm 2 Placebo</title>
          <description>Placebo
Placebo: 80 mg placebo once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="3.0"/>
                    <measurement group_id="B2" value="50" spread="2.9"/>
                    <measurement group_id="B3" value="50" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="4.2"/>
                    <measurement group_id="B2" value="36.1" spread="3.4"/>
                    <measurement group_id="B3" value="37.3" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Circulating LPS</title>
        <description>Plasma lipopolysaccharide (LPS) will be measured both in the fasting state and after a lipid-rich meal in obese subjects (Pre-Treatment: 0, 4 and 8 hr timepoints). The subjects will then be treated with the antibiotic rifaximin for 12 weeks to substantially reduce gut bacteria. LPS measurements at fasting and after a lipid-rich meal will be repeated (Post-Treatment: 0, 4 and 8 hr timepoints). The lipid tolerance tests before and after treatment with rifaximin will be assessed to determine whether there is a reduction in post-prandial LPS. LPS measurements were obtained using a modified LAL Assay.</description>
        <time_frame>0, 4 and 8 hours at Baseline, and 0, 4 and 8 hours after 12 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 Rifaximin SSD</title>
            <description>Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
Rifaximin SSD: Study Drug dosing will be 80 mg SSD once daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Placebo</title>
            <description>Placebo
Placebo: 80 mg placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating LPS</title>
          <description>Plasma lipopolysaccharide (LPS) will be measured both in the fasting state and after a lipid-rich meal in obese subjects (Pre-Treatment: 0, 4 and 8 hr timepoints). The subjects will then be treated with the antibiotic rifaximin for 12 weeks to substantially reduce gut bacteria. LPS measurements at fasting and after a lipid-rich meal will be repeated (Post-Treatment: 0, 4 and 8 hr timepoints). The lipid tolerance tests before and after treatment with rifaximin will be assessed to determine whether there is a reduction in post-prandial LPS. LPS measurements were obtained using a modified LAL Assay.</description>
          <units>EU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment 0hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="0.40"/>
                    <measurement group_id="O2" value="1.86" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-treatment 4hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.66" spread="2.93"/>
                    <measurement group_id="O2" value="10.00" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-treatment 8hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.26"/>
                    <measurement group_id="O2" value="1.04" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment 0hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.35"/>
                    <measurement group_id="O2" value="1.86" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment 4hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.45" spread="1.87"/>
                    <measurement group_id="O2" value="9.97" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment 8hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="0.49"/>
                    <measurement group_id="O2" value="2.29" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the pre- and post-treatment timecourse between untreated and rifaximin-treated participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The p-value was calculated to be &gt;0.05.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tissue Inflammation</title>
        <description>Subjects will undergo a baseline fat biopsy (pre-treatment). They will then be treated with rifaximin for 12 weeks and biopsies will be repeated to determine if disruption of the microbiota reduces tissue inflammation. Data are reported as normalized mRNA expression levels (arbitrary units) of TNFalpha.</description>
        <time_frame>Pre-Treatment (baseline) and Post-Treatment (12 weeks after baseline).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 Rifaximin SSD</title>
            <description>Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
Rifaximin SSD: Study Drug dosing will be 80 mg SSD once daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Placebo</title>
            <description>Placebo
Placebo: 80 mg placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Tissue Inflammation</title>
          <description>Subjects will undergo a baseline fat biopsy (pre-treatment). They will then be treated with rifaximin for 12 weeks and biopsies will be repeated to determine if disruption of the microbiota reduces tissue inflammation. Data are reported as normalized mRNA expression levels (arbitrary units) of TNFalpha.</description>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.25"/>
                    <measurement group_id="O2" value="1.30" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.25"/>
                    <measurement group_id="O2" value="1.46" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (change in placebo pre- and post-treatment versus change in rifaximin pre- and post-treatment).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>unpaired Student's t-test</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Improved Insulin Sensitivity</title>
        <description>We hypothesize that a change in the microbial flora with rifaximin will alter plasma LPS, adipose tissue inflammation, and insulin sensitivity. Therefore, we will examine, before and after rifaximin/placebo treatment: 1. LPS associated with lipoproteins, 2. insulin sensitivity and hepatic glucose production, 3. plasma inflammatory markers (TNFα, IL-6, MCP-1, adiponectin), 4. adipose inflammatory markers (CD68, MCP1, TNFα, PAI1, IL12, IL10, TLR4 and others).</description>
        <time_frame>Up to 12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1 Rifaximin SSD</title>
          <description>Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
Rifaximin SSD: Study Drug dosing will be 80 mg SSD once daily</description>
        </group>
        <group group_id="E2">
          <title>Arm 2 Placebo</title>
          <description>Placebo
Placebo: 80 mg placebo once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Philip Kern</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>859-323-2232</phone>
      <email>pake222@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

